Veradermics
MANE | NYSE
$130.03
-$9.66 (-6.92%)
Nov 2, 2026, 3:42 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|---|
Cash & Equivalents | 319.33M | 168.41M | 21.77M | 5.66M | 53.08M |
Short-Term Investments | 500.56M | 222.39M | 120.1M | 9.48M | n/a |
Long-Term Investments | n/a | 1.23M | n/a | n/a | 3.85M |
Other Long-Term Assets | n/a | 266K | n/a | n/a | n/a |
Receivables | n/a | 1.65M | 1.26M | 1.23M | 1.38M |
Inventory | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 2.72M | 602K | 3.77M | 273K | 38K |
Total Current Assets | 824.75M | 397.07M | 152.49M | 18.71M | 55.54M |
Property-Plant & Equipment | 989K | 21K | 125K | 84K | n/a |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 989K | 1.51M | 125K | 84K | 3.85M |
Total Assets | 825.74M | 398.58M | 152.62M | 18.8M | 59.38M |
Account Payables | 5.92M | 1.07M | 2.13M | 1.99M | 2.25M |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | n/a | n/a | n/a | n/a | n/a |
Other Current Liabilities | 379K | 39K | 47K | 1.11M | 1.44M |
Total Current Liabilities | 11.69M | 6.72M | 9.15M | 5.69M | 4.72M |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | 264.48M | 109.1M | n/a |
Total Long-Term Liabilities | 428K | n/a | 264.48M | 109.12M | n/a |
Total Liabilities | 12.12M | 6.72M | 273.63M | 114.81M | 4.72M |
Total Debt | 428K | n/a | 4K | 16K | n/a |
Book Value | 813.61M | 391.87M | -121.01M | -96.02M | 54.67M |
Book Value Per Share | 20.12 | 10.49 | -3.24 | n/a | 0.27 |
Common Stock | 1K | 1K | 1K | 1K | 1K |
Retained Earnings | -174.16M | -150.65M | -123.42M | -97.38M | -49.23M |
Comprehensive Income | -1.49M | -524K | 60K | n/a | n/a |
Shareholders Equity | 813.61M | 391.87M | -121.01M | -96.02M | 54.67M |
Total Investments | 500.56M | 223.61M | 120.1M | 9.48M | 3.85M |
Add to Watchlist
Select watchlists to add or remove MANE